China: Foreign investment at four-year low as competition regulation questioned
As critics of China’s antitrust regime have begun to warn that foreign investment would likely dwindle in the nation, reports say the numbers are already showing such effects.
According to the Financial Times, foreign investment in China is at its lowest level in four years thanks to price-fixing and other antitrust investigations that critics say unfairly target foreign companies.
Reports added that investment in the nation dropped to $7.2 billion in August, its lowest level since July 2010. The paper calculated the data itself.
Further, the Financial Times found, investment dropped 14 percent from the same month last year.
According to reports, this is also the first time foreign direct investment fell by more than 10 percent for two months in a row since the 2009 global financial crisis.
Lobbyists, consumer advocated and government representatives have heightened their criticism of Chinese competition policy, arguing that recent investigations into companies like Qualcomm, Microsoft, Chrysler and Audi give the impression that China is unfairly targeting foreign companies to promote its own domestic businesses.
Full content: IR Magazine
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas